Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36166004)

  • 1. A Novel B7-H6-Targeted IgG-Like T Cell-Engaging Antibody for the Treatment of Gastrointestinal Tumors.
    Zhang W; Auguste A; Liao X; Walterskirchen C; Bauer K; Lin YH; Yang L; Sayedian F; Fabits M; Bergmann M; Binder C; Corrales L; Vogt AB; Hudson LJ; Barnes MP; Bisht A; Giragossian C; Voynov V; Adam PJ; Hipp S
    Clin Cancer Res; 2022 Dec; 28(23):5190-5201. PubMed ID: 36166004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer.
    Hipp S; Voynov V; Drobits-Handl B; Giragossian C; Trapani F; Nixon AE; Scheer JM; Adam PJ
    Clin Cancer Res; 2020 Oct; 26(19):5258-5268. PubMed ID: 32554516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo.
    Zhang T; Wu MR; Sentman CL
    J Immunol; 2012 Sep; 189(5):2290-9. PubMed ID: 22851709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
    Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
    Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint molecules B7-H6 and PD-L1 co-pattern the tumor inflammatory microenvironment in human breast cancer.
    Cherif B; Triki H; Charfi S; Bouzidi L; Kridis WB; Khanfir A; Chaabane K; Sellami-Boudawara T; Rebai A
    Sci Rep; 2021 Apr; 11(1):7550. PubMed ID: 33824367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of costimulatory molecule B7-H3 expression on CD3(+) T cells in colorectal carcinoma.
    Mao Y; Sun J; Wang WP; Zhang XG; Hua D
    Chin Med J (Engl); 2013 Aug; 126(16):3035-8. PubMed ID: 23981607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer.
    Lutz MS; Zekri L; We├čling L; Berchtold S; Heitmann JS; Lauer UM; Jung G; Salih HR
    Front Immunol; 2023; 14():1163136. PubMed ID: 37122707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression, crystallization and X-ray diffraction analysis of a complex between B7-H6, a tumor cell ligand for the natural cytotoxicity receptor NKp30, and an inhibitory antibody.
    Xu X; Li Y; Gauthier L; Chen Q; Vivier E; Mariuzza RA
    Acta Crystallogr F Struct Biol Commun; 2015 Jun; 71(Pt 6):697-701. PubMed ID: 26057798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers.
    Mathur D; Root AR; Bugaj-Gaweda B; Bisulco S; Tan X; Fang W; Kearney JC; Lucas J; Guffroy M; Golas J; Rohde CM; Stevens C; Kamperschroer C; Kelleher K; Lawrence-Henderson RF; Upeslacis E; Yao J; Narula J; LaVallie ER; Fernandez DR; Buetow BS; Rosfjord E; Bloom L; King LE; Tchistiakova L; Nguyen A; Sapra P
    Clin Cancer Res; 2020 May; 26(9):2188-2202. PubMed ID: 31996389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers.
    Zekri L; Lutz M; Prakash N; Manz T; Klimovich B; Mueller S; Hoerner S; Hagelstein I; Engel M; Chashchina A; Pfluegler M; Heitmann JS; Jung G; Salih HR
    Mol Ther; 2023 Apr; 31(4):1033-1045. PubMed ID: 36793213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.
    Pekar L; Klausz K; Busch M; Valldorf B; Kolmar H; Wesch D; Oberg HH; Krohn S; Boje AS; Gehlert CL; Toleikis L; Krah S; Gupta T; Rabinovich B; Zielonka S; Peipp M
    J Immunol; 2021 Jan; 206(1):225-236. PubMed ID: 33268483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B7-H6 as an efficient target for T cell-induced cytotoxicity in haematologic malignant cells.
    Sun X; Zhao J; Ma L; Sun X; Ge J; Yu Y; Ma J; Zhang M
    Invest New Drugs; 2021 Feb; 39(1):24-33. PubMed ID: 32770284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B7-H6 expression correlates with cancer progression and patient's survival in human ovarian cancer.
    Zhou Y; Xu Y; Chen L; Xu B; Wu C; Jiang J
    Int J Clin Exp Pathol; 2015; 8(8):9428-33. PubMed ID: 26464699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The B7 Family Member B7-H6: a New Bane of Tumor.
    Chen Y; Mo J; Jia X; He Y
    Pathol Oncol Res; 2018 Oct; 24(4):717-721. PubMed ID: 29086181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B7-H6 protein expression has no prognostic significance in human gastric carcinoma.
    Chen XJ; Shen J; Zhang GB; Chen WC
    Pathol Oncol Res; 2014 Jan; 20(1):203-7. PubMed ID: 24242703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
    Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
    Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
    [No Abstract]   [Full Text] [Related]  

  • 17. Development of T-cell engagers selective for cells co-expressing two antigens.
    Dicara DM; Bhakta S; Go MA; Ziai J; Firestein R; Forrest B; Gu C; Leong SR; Lee G; Yu SF; Polson AG; Agard NJ
    MAbs; 2022; 14(1):2115213. PubMed ID: 36206404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B7-H6 expression is induced by lipopolysaccharide and facilitates cancer invasion and metastasis in human gliomas.
    Che F; Xie X; Wang L; Su Q; Jia F; Ye Y; Zang L; Wang J; Li H; Quan Y; You C; Yin J; Wang Z; Li G; Du Y; Wang L
    Int Immunopharmacol; 2018 Jun; 59():318-327. PubMed ID: 29679856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifunctional NK Cell-Engaging Antibodies Targeting EGFR and NKp30 Elicit Efficient Tumor Cell Killing and Proinflammatory Cytokine Release.
    Klausz K; Pekar L; Boje AS; Gehlert CL; Krohn S; Gupta T; Xiao Y; Krah S; Zaynagetdinov R; Lipinski B; Toleikis L; Poetzsch S; Rabinovich B; Peipp M; Zielonka S
    J Immunol; 2022 Nov; 209(9):1724-1735. PubMed ID: 36104113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.
    Peipp M; Derer S; Lohse S; Staudinger M; Klausz K; Valerius T; Gramatzki M; Kellner C
    Oncotarget; 2015 Oct; 6(31):32075-88. PubMed ID: 26392331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.